SI
SI
discoversearch

Biotech / Medical
BMY (bristol myers squibb)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
142 20 0 BMY
Emcee:  trevor john wilkinson Type:  Unmoderated
Anybody any comments

Zacks rating 2
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
142If someone plot CM-227 (High TMB) chemo KM OS line on KN-189 OS KM plots, there Miljenko Zuanic-April 16
141I voted "VO-DO". New-comers anti-PD1 may bring some clarity!!!???Miljenko Zuanic-April 16
140No one seems to know the answer. I just voted in Matt Herper's survey by selDewDiligence_on_SI-April 16
139Pem-Nivo gap (NSCLC) is wide open now. So, the Qs are WHY! What is secondary (ofMiljenko Zuanic-April 16
138Now that Novatris has a deal how long will it be before PFE or BMY buys out LDS?james flannigan-March 19
137I would go with neutral, with combo shoving trend toward survival benefit. HowevMiljenko Zuanic-March 12
136Strangely, all biotech tweeps on my Twitter stream are saying the MYSTIC delay DewDiligence_on_SI-March 12
135fiercepharma.com If delay in OS-read out is indicator for Imf. + tremelimumab Miljenko Zuanic-March 12
134One do not need to be "Salamon" to figure out that hTMB will hurt respMiljenko Zuanic-February 5
133While TMB per se is not BS, some of the stuff BMY said about TMB in the context DewDiligence_on_SI-February 5
132IMO, Eliquis is not sufficient. It is shared with PFE. They are investing $$$$ Miljenko Zuanic-February 5
131Ex-US, Opdivo still has a formidable advantage relative to Keytruda in reimburseDewDiligence_on_SI-February 5
130From JPM notes: <Regarding IO... - Opdivo sales for 4Q were $1,361M (cons $Miljenko Zuanic-February 5
129Still can not explain why so much difference in activity (for NSCLC) between OpdMiljenko Zuanic-February 5
128What kind of F-ing SHIT is this: <The Opdivo plus Yervoy combination cohort iMiljenko Zuanic-January 21
127I want to thanks all those who shorted at 2Q-results, so give me a chance to addMiljenko Zuanic-8/29/2017
126Not to forget that marker analysis and prediction of the response magnitude (RR Miljenko Zuanic-7/27/2017
125In light of the MISTIC failure (for PDL1>25%, NSCLC), maybe it is premature tMiljenko Zuanic-7/27/2017
124Bullish crossover in MACD and Stochastic oscillator. [graphic]hollyhunter-7/4/2017
123Agreed (eom).DewDiligence_on_SI-6/15/2017
122After listening Thomas Lynch presentation at GS, I become confident that he kMiljenko Zuanic-6/14/2017
121 AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers SZoro99-8/15/2016
120Bristol-Myers Squibb ($BMY +1.87%) was upgraded to 'Buy' from 'Neutrmore100-12/3/2015
119 Looks like no one is home but this new appears to have popped the stock up ovThehammer-10/30/2014
118 2:00 pm ET 03/23/2011 - Reuters * Arthritis drug leflunomide shows promise agaiArthur Radley-3/23/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.